(44 days)
Not Found
Not Found
No
The summary describes a quantitative determination of a chemical marker using automated chemistry analyzers, with no mention of AI, ML, image processing, or any other technology typically associated with AI/ML in medical devices.
No.
The device is intended for in vitro diagnostic use to measure AST levels, which is used for diagnosis and treatment monitoring, not to directly treat or prevent a disease or condition.
Yes
The device is intended for the "quantitative determination of aspartate amino transferase (AST) in human serum" and these measurements are "used in the diagnosis and treatment of certain types of liver and heart diseases." This directly indicates its use in diagnosing conditions.
No
The intended use describes a quantitative determination of AST in human serum on automated chemistry analyzers, which implies a physical reagent and analyzer system, not a software-only device.
Based on the provided information, yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" explicitly states it is "Intended for the In Vitro, quantitative determination of aspartate amino transferase (AST) in human serum". The term "In Vitro" is the defining characteristic of an IVD.
- Sample Type: It specifies the analysis of "human serum", which is a biological sample taken from the body.
- Purpose: The measurements are used in the "diagnosis and treatment of certain types of liver and heart diseases", indicating a medical purpose for the test results.
The lack of information in other sections (Device Description, Performance Studies, etc.) does not negate its classification as an IVD based on the clear statement in the Intended Use.
N/A
Intended Use / Indications for Use
Intended for the In Vitro, quantitative determination of aspartate amino transferase (AST) in human serum on automated chemistry analyzers.
Aspartate amino transferase measurements are used in the diagnosis and treatment of certain types of liver and heart diseases.
Product codes
CIT
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1100 Aspartate amino transferase (AST/SGOT) test system.
(a)
Identification. An aspartate amino transferase (AST/SGOT) test system is a device intended to measure the activity of the enzyme aspartate amino transferase (AST) (also known as a serum glutamic oxaloacetic transferase or SGOT) in serum and plasma. Aspartate amino transferase measurements are used in the diagnosis and treatment of certain types of liver and heart disease.(b)
Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized caduceus-like symbol with three lines representing the branches of government. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the symbol in a circular fashion.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
DEC 2 1 2001
Mr. David Johnston Technical Director JAS Diagnostics, Inc. 7220 N.W. 58th Street Miami, FL 33166
Re:
K013698 Trade/Device Name: AST (SGOT) REAGENT Regulation Number: 21 CFR 862.1100 Regulation Name: Aspartate amino transferase (AST/SGOT) test system Regulatory Class: Class II Product Code: CIT Dated: October 23, 2001 Received: November 07, 2001
Dear Mr. Johnston:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket This letter will and in you of substantial equivalence of your device to a legally marketed nouncation. THE I will in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at additionally 60710 for questions on the promotion and advertising of your device, (2017) 594-1568) - Frances at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small miormation on Jour respeal and Consumer Assistance at its toll-free number (800) 638-2041 or 1701) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
510(k) Number (if known): Device Name: _ AST (SGOT) REAGENT Indications for Use:
Intended for the In Vitro, quantitative determination of aspartate amino transferase (AST) in human serum on automated chemistry analyzers.
Aspartate amino transferase measurements are used in the diagnosis and treatment of certain types of liver and heart diseases.
Alway Dast for Jear booper
(Division Sign-Off)
ical I aboratory Devices
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
OR
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Prescription Use
(Per 21 CFR 801.109)
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)